首页> 外文期刊>Experimental and therapeutic medicine >Effects of tirofiban on stent thrombosis, Hs-CRP, IL-6 and sICAM-1 after PCI of acute myocardial infarction
【24h】

Effects of tirofiban on stent thrombosis, Hs-CRP, IL-6 and sICAM-1 after PCI of acute myocardial infarction

机译:Tirofiban对急性心肌梗死PCI后支架血栓形成,HS-CRP,IL-6和SICAM-1的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Effects of tirofiban on stent thrombosis, high-sensitivity C-reactive protein (Hs-CRP), interleukin-6 (IL-6) and soluble intercellular adhesion molecule-1 (sICAM-1) after percutaneous coronary intervention (PCI) of acute myocardial infarction (AMI) were investigated. A total of 94 AMI patients receiving PCI in Shouguang City People's Hospital from January 2016 to September 2016 were selected and randomly divided into control (n=47) and observation group (n=47). The control group was treated with aspirin + clopidogrel before and after operation, while the observation group was treated with tirofiban based on the treatment of control group. The postoperative stent thrombosis was compared between the two groups, and the serum Hs-CRP, IL-6 and sICAM-1 levels before operation and at 24 and 48 h after operation were also compared between two groups. Moreover, the incidence rates of adverse reactions in the groups were observed. Finally, patients were followed-up for 1 year to observe the total incidence rate of adverse cardiac events and life quality of patients in both groups. The thrombolysis in myocardial infarction flow grading in observation after treatment was significantly superior to that in control group (P0.05). The levels of Hs-CRP, IL-6 and sICAM-1 in both groups at 24 and 48 h after operation were significantly decreased compared with those before operation, and they were decreased more obviously in observation group (P0.05); there were no significant differences in the incidence rates of adverse reactions between the groups (P0.05). Besides, the 1-year follow-up showed that the total incidence rate of adverse cardiac events in observation was significantly lower than that in control group, and the life quality scores were obviously higher than those in control group (P0.05). The treatment of AMI patients undergoing PCI with tirofiban can effectively prevent stent thrombosis, and alleviate the inflammatory response of patients, it is safe and reliable with important clinical significance.
机译:急性心肌术后冠状动脉介入(PCI)后促替氟班对支架血栓形成,高敏率C反应蛋白(HS-CRP),白细胞介素-6(IL-6)和可溶性细胞间粘附分子-1(SICAM-1)研究了梗塞(AMI)。从2016年1月到2016年1月在寿光市人民医院接受PCI共有94例AMI患者,并随机分为控制(n = 47)和观察组(n = 47)。在手术前后用阿司匹林+氯吡格雷治疗对照组,同时基于对对照组的治疗用替洛菲班处理观察组。在两组之间比较了两组和血清HS-CRP,IL-6和SICAM-1水平之间的术后支架血栓形成,并且在操作后24和48小时,在两组之间也比较。此外,观察到组中不良反应的发病率。最后,患者随访1年,以观察两组患者的不良心脏事件和生命质量的总发生率。在治疗后观察后心肌梗死流动分级的溶栓显着优于对照组(P <0.05)。与手术前24和48小时,在操作前24和48小时的两组中HS-CRP,IL-6和SICAM-1的水平显着降低,并且在观察组中更明显地减少(P <0.05);组之间存在不良反应的发病率没有显着差异(P&GT; 0.05)。此外,1年的随访表明,观察中不良心脏事件的总发生率显着低于对照组,并且生活质量评分明显高于对照组(P <0.05)。治疗患有替洛菲班的PCI的AMI患者可以有效防止支架血栓形成,并缓解患者的炎症反应,这是安全可靠的,具有重要的临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号